Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab vs Infliximab in RA Inadequate Responders to Anti-TNF
NCT00808210Phase 2Terminated
- Sponsor
- Genentech
- Start
- Mar 2009
- Primary completion
- Nov 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ocrelizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Genentech. Primary endpoint: Change From Baseline in Disease Activity Score 28-Joint Count (Erythrocyte Sedimentation Rate) at 20 weeks. Started Mar 2009; status: terminated.
02
Drugs
ocrelizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00808210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00808210.